This approach allows for the classification of tumors into four clinically relevant subtypes: prostatic adenocarcinoma (AR+/NE−), NEPC (AR−/NE+), amphicrine carcinoma (AR+/NE+) and double negative CRPC (AR−/NE−) 20,37. This evidence concerns the gene ELANE and prostate adenocarcinoma.